The purpose of the PALLAS trial (NCT02513394), including 5796 patients, was to determine whether adjuvant endocrine therapy with palbociclib would improve invasive disease-free survival (iDFS) over endocrine therapy alone for HR+/HER2− early breast cancer (EBC) [56]. The gene discussed is HR; the disease is breast carcinoma.